Pharma BD Deal Intelligence
Gilead Sciences is paying $375 million in cash and $200 million in equity for a 10-year option-based partnership with Arcus Biosciences covering the company's…
Gilead Sciences will pay up to $5 billion to access a portfolio of next-generation cancer drugs from Arcus Biosciences, including a closely-watched anti-TIGIT…
Gilead and Arcus continue to differentiate their domvanalimab anti-TIGIT program from Roche's failed tiragolumab and Merck's mixed vibostolimab readouts,…
Source summaries from our enrichment pipeline; follow links for originals.
All 18 sources with sentiment breakdown →
Gilead Sciences and Arcus Biosciences entered a 10-year collaboration to develop and commercialize next-generation immuno-oncology therapies. Gilead paid $375M upfront and made a $200M equity investment, with up to $4.475B in option exercise fees and milestone payments. The deal covers Arcus's pipeline of anti-TIGIT (domvanalimab), anti-PD-1, anti-CD73, and other IO assets. This was a partnership with an equity stake (later ~33%), not an acquisition. The anti-TIGIT thesis subsequently collapsed: the Phase 3 STAR-221 (upper GI) study was discontinued for futility in December 2025 and STAR-121 (1L NSCLC) was discontinued for futility in April 2026. On April 20, 2026 Gilead declined the option-continuation payment, ending its option period on July 14, 2026 and forgoing options to Arcus's CCR6/CD89/CD40L programs while retaining existing options on AB801, AB598, AB102 and a TNF inhibitor. Arcus has refocused on its wholly-owned HIF-2a inhibitor casdatifan (Phase 3 PEAK-1 in ccRCC).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Arcus Biosciences, Inc. (this deal) | 2020 | $5.0B | 46 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2020 deals · Gilead Sciences Inc. deals · Oncology deals